Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
Valuation and Earnings
This table compares Arbutus Biopharma and MiMedx Group”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arbutus Biopharma | $181.49 million | 3.45 | -$33.50 million | $1.13 | 3.62 |
| MiMedx Group | $418.63 million | 1.12 | $48.58 million | ($0.13) | -24.69 |
MiMedx Group has higher revenue and earnings than Arbutus Biopharma. MiMedx Group is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Arbutus Biopharma and MiMedx Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arbutus Biopharma | 0 | 1 | 0 | 0 | 2.00 |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
MiMedx Group has a consensus target price of $8.14, indicating a potential upside of 153.67%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Arbutus Biopharma.
Profitability
This table compares Arbutus Biopharma and MiMedx Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arbutus Biopharma | 121.17% | 129.12% | 89.26% |
| MiMedx Group | -6.32% | 2.39% | 1.85% |
Institutional and Insider Ownership
43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Arbutus Biopharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
About Arbutus Biopharma
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development.
About MiMedx Group
MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
